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ABSTRACT
Oropouche virus (OROV) is a member of theOrthobunyavirus genus in the Bunyaviridae family and a prominent cause of in-
sect-transmitted viral disease in Central and South America. Despite its clinical relevance, little is known about OROV patho-
genesis. To define the host defense pathways that control OROV infection and disease, we evaluated OROV pathogenesis and
immune responses in primary cells andmice that were deficient in the RIG-I-like receptor signaling pathway (MDA5, RIG-I, or
MAVS), downstream regulatory transcription factors (IRF-3 or IRF-7), beta interferon (IFN-), or the receptor for type I IFN
signaling (IFNAR). OROV replicated to higher levels in primary fibroblasts and dendritic cells lackingMAVS signaling, the tran-
scription factors IRF-3 and IRF-7, or IFNAR than in wild-type (WT) cells. In mice, deletion of IFNAR, MAVS, or IRF-3 and IRF-7
resulted in uncontrolled OROV replication, hypercytokinemia, extensive liver damage, and death, whereasWT congenic animals
failed to develop disease. Unexpectedly, mice with a selective deletion of IFNAR onmyeloid cells (CD11c Cre Ifnarf/f or LysM
Cre Ifnarf/f) did not sustain enhanced disease with OROV or a selective (flox/flox) deletion La Crosse virus, a closely related
encephalitic orthobunyavirus. In bone marrow chimera studies, recipient irradiated Ifnar/mice reconstituted withWT hema-
topoietic cells sustained high levels of OROV replication and liver damage, whereasWTmice reconstituted with Ifnar/ bone
marrow were resistant to disease. Collectively, these results establish a dominant protective role for MAVS, IRF-3 and IRF-7, and
IFNAR in restricting OROV infection and tissue injury and suggest that IFN signaling in nonmyeloid cells contributes to the
host defense against orthobunyaviruses.
IMPORTANCE
Oropouche virus (OROV) is an emerging arthropod-transmitted orthobunyavirus that causes episodic outbreaks of a debilitat-
ing febrile illness in humans in countries of South and Central America. The continued expansion of the range and number of its
arthropod vectors increases the likelihood that OROVwill spread into new regions. At present, the pathogenesis of OROV in
humans or other vertebrate animals remains poorly understood. To define cellular mechanisms of control of OROV infection,
we performed infection studies in a series of primary cells andmice that were deficient in key innate immune genes involved in
pathogen recognition and control. Our results establish that a MAVS-dependent type I IFN signaling pathway has a dominant
role in restricting OROV infection and pathogenesis in vivo.
Oropouche virus (OROV) is an arthropod-transmitted virusof the family Bunyaviridae, genus Orthobunyavirus, and se-
rogroup Simbu. OROV has a trisegmented genome, comprised of
three single-stranded negative-sense RNA segments: large (L),
medium (M), and small (S). L encodes the viral RNA polymerase,
M encodes the viral surface glycoproteins (Gc andGn) and a non-
structural protein (NSm), and S encodes the nucleocapsid (N)
protein and a small nonstructural protein (NSs) in overlapping
reading frames (1). Although details about its cellular life cycle
remain poorly characterized,OROVentry is associatedwith clath-
rin-coated pits, endosomal acidification, and membrane fusion,
which facilitates nucleocapsid release into the cytoplasm (2). The
receptors of OROV remain uncharacterized, although Gc is im-
plicated in host cell attachment (3). While the precise replication
strategy used by OROV has not been described, it likely occurs in
the cytoplasm, similar to other bunyaviruses. Bunyavirus mRNA
transcription is primed by “cap-snatching” from cytoplasmic host
cellular mRNAs through activities of the viral L andN proteins (4,
5). Genome replication follows via a positive-sense strand inter-
mediate (6). Translation of the L and S segment-encoded proteins
occurs on free ribosomes in the cytoplasm, and translation of M
polypeptides occurs on endoplasmic reticulum (ER)-bound ribo-
somes, resulting in a nascent polypeptide that is cleaved
cotranslationally to generate Gn and Gc (7). Virus assembly
and maturation take place in association with ER and Golgi
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membranes (8), and virion release occurs by fusion of vesicular
bodies with the plasma membranes or via direct budding at the
plasma membrane (7).
Since the 1960s, OROV has caused periodic outbreaks of a
debilitating febrile illness, with more than 30 epidemics and
500,000 infected people in Brazil, Peru, Trinidad, Panama, and
Suriname (9–11). Although OROV was described initially as a
sylvatic virus circulating between sloths (Bradypus tridactylus),
monkeys (Saguinus spp., Saimiri spp., and Alouatta belzebul), and
other animals, with only episodic outbreaks in humans (12), re-
cent studies indicate that OROV circulates in urban areas of South
America and was associated with approximately 2 to 6% of undif-
ferentiated febrile patients in 13 locations in Ecuador, Peru, Bo-
livia (9, 13), and Brazil (14). Consistent with this observation, the
seroprevalence for OROV in urban areas in the Amazon ranges
between 15 and 33% (13, 15). Climate change, expansion and
dissemination of arthropod vectors, and human travel increase
the likelihood that OROV will emerge as a pathogen of greater
significance in new areas. Several arthropod vectors contribute to
OROV transmission, including Culicoides paraensis and Culex
quinquefasciatus in the urban cycle and Aedes serratus and Coquil-
lettidia venezuelensis in the sylvatic cycle. Other species of Aedes
mosquitoes, including Aedes albopictus, can sustain OROV infec-
tion in laboratory settings (16).
In humans, OROV infection causes Oropouche fever, a severe
febrile illness associated with headache, myalgia, arthralgia, mal-
aise, and skin rash. Viremia is detected only during the first few
days of infection. Hemorrhagic phenomena (petechiae, epistaxis,
and gingival bleeding) have been reported in some patients (17).
Althoughmost patients with Oropouche fever recover within 2 to
3 weeks of initial infection without long-term sequelae (12),
symptoms can persist for months and, surprisingly, relapses are
common (12). In some patients, OROV infection progresses to
meningitis and/or encephalitis (18–20). Indeed, OROV was de-
tected in the cerebrospinal fluid of almost 7% of patients with
meningoencephalitis who were suspected of having an acute viral
infection of the central nervous system (CNS) in some settings
(18, 19).Neurological signs and symptoms in patientswithOROV
fever include vertigo, lethargy, diplopia, nystagmus, and nuchal
rigidity (12, 20).
Despite its potential for further geographical spread, little is
known about OROV pathogenesis. In two animal models (adult
golden hamster [Mesocricetus auratus] and neonatal BALB/c
mice),OROVwas detected in the brain and spinal cord, associated
with pathological evidence of encephalitis, and resulted in lethal-
ity (30% of hamsters [21] and 85% of neonatal mice [22]). Re-
cently, a study suggested that during the early phases of infection,
OROV disseminates to the CNS via the spinal cord and subse-
quently transits to the brain, presumably through retrograde
axonal transport (23). However, OROV has not been reported to
replicate efficiently or cause disease in adult immunocompetent
mice, and little is known about the host factors that restrict OROV
infection in peripheral organs or in the CNS tissues of these ani-
mals.
Analogous to other arthropod-borne viruses (e.g., dengue [24]
and chikungunya [25]), we hypothesized that the limited infec-
tion in adult mice might reflect restriction of OROV by innate
immune host defense pathways inmaturemurine cells. The type I
interferon (IFN) signaling network is essential for antiviral de-
fense and has a pivotal role in age-dependent mortality in mice
(25). This response is initiated by recognition of non-self patho-
gen-associated molecular patterns (PAMPs), including viral nu-
cleic acids, and by host pattern recognition receptors (PRRs), in-
cluding Toll-like receptors (TLR3 and TLR7) and RIG-I-like
receptors (RLRs; RIG-I andMDA5) (26–29). TLRs and RLRs rec-
ognize distinct RNA PAMPs in the endosome and cytoplasm, re-
spectively, and activate signaling cascades to initiate host defense
responses. Both PRR pathways can induce nuclear localization of
the transcription factors IRF-3, IRF-7, and NF-B to induce the
expression of type I IFN and proinflammatory cytokines (30).
Type I IFN signaling induces an antiviral state by triggering ex-
pression of several hundred IFN-stimulated genes (ISGs), which
block viral entry, replication, translation, and assembly as well as
modulate inflammation and adaptive immunity (31).
Although little is known about how the innate immune system
restricts OROV, type I IFN protects against related orthobunyavi-
ruses (32), even though several genus members have mechanisms
to inhibit type I IFN production by infected cells (33–35). Adult
mice deficient in the type I IFN receptor (Ifnar/) are more vul-
nerable to infection by La Crosse (LACV), Schmallenberg (SBV),
and Bunyamwera (BUNV) viruses than wild-type (WT)mice (34,
36, 37). Members of the more distantly related Phlebovirus and
Nairovirus genera, including Rift Valley fever virus (RVFV) and
Crimean-Congohemorrhagic fever virus (CCHFV), also aremore
pathogenic in Ifnar/ mice (38, 39). IRF-3- and IRF-7-depen-
dent transcription contributes to the control of LACV infection in
vivo (40), as their combined deficiency resulted in more rapid
death (40, 41). However, a deficiency of MAVS paradoxically re-
sulted in an improved clinical outcome after LACV infection (40),
suggesting that under certain circumstances MAVS-dependent
signaling may cause neuronal pathogenesis in vivo.
To begin to define the role of PRRs and type I IFN induction
and signaling pathways on OROV pathogenesis, we studied the
morbidity, mortality, tissue tropism, and cytokine responses from
OROV-infected mice with targeted gene deletions in IFNAR,
IFN-, MDA5, MAVS, IRF-3, and IRF-7. In parallel, we analyzed
the kinetics of OROV infection ex vivo in primary fibroblasts
(MEFs), macrophages (M), and dendritic cells (DCs). Our ex-
periments show a prominent protective role forMAVS, IRF-3 and
IRF-7, and IFNAR in restrictingOROV infection and tissue injury
and establish that type I IFN signaling in nonmyeloid cells likely
contributes to the antiviral response against orthobunyaviruses.
MATERIALS AND METHODS
Viruses and cells.TheOROV strain (Bean 19991)was provided by Eurico
Arruda (Ribeirão Preto, Brazil) and passaged three times in Vero cells to
produce the virus stock. This stock was clarified by centrifugation (5,000
 g for 5 min) and stored at 80°C. The titer of the stock virus was
determined by focus-forming assay and calculated as 2.0  107 focus-
forming units (FFU) perml. All experiments with OROVwere conducted
under enhanced biosafety level 3 (BSL3) and animal (A)-BSL3 contain-
ment at Washington University with the appropriate personal protective
equipment and approval from the United States Department of Agricul-
ture. The LACV strain (original strain) was provided generously by An-
drew Pekosz (Johns Hopkins University, Baltimore, MD, USA) and pas-
saged twice in Vero cells to produce a virus stock. This stock was clarified
and stored at 80°C. The titer of LACV was calculated as 2.7  107
FFU/ml using the monoclonal antibodies (MAb; 807-31 and 807-33) that
also were provided by Andrew Pekosz (42, 43). Experiments with LACV
were conducted in BSL2 and A-BSL3 facilities.
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Ethics statement. This study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health (44) after approval by the
Institutional Animal Care andUseCommittee at theWashingtonUniver-
sity School ofMedicine (assurance number A3381-01). All injections with
virus were performed under anesthesia with ketamine hydrochloride (80
mg/kg of body weight) and xylazine (15 mg/kg).
Mouse experiments. All mice were on a C57BL/6 background. WT
mice (CD45.1 and CD45.2) were purchased from Jackson Laboratories
and/or bred in a specific-pathogen-free facility atWashington University.
Ifnar/, Ifnb/, Mda5/, Mavs/, Irf3/, Irf7/, and Irf3/ 
Irf7/ (double-knockout [DKO]) mice were described previously (45–
50). CD11c Cre Ifnarf/f, LysM Cre Ifnarf/f, and Cre Ifnarf/f mice also
were described previously (51). All infections were performed by subcu-
taneous injection in the footpad with 106 FFU of OROV and 105 or 106
FFU of LACV in a volume of 50 l using 5- to 6-week-old mice. All
animals were monitored for survival and weight loss for 21 days.
Bone marrow chimera and transfers. Bone marrow cells were col-
lected from adult C57BL/6WT (CD45.1) or Ifnar/ (CD45.2) mice and
transferred adoptively (107 cells per animal) by retroorbital injection into
4-week-old 800-cGy-irradiated WT (CD45.1 or CD45.2) or Ifnar/
mice. Eight weeks later, reconstitution was validated by flow cytometry
and mice were infected with OROV. Four days later, serum and tissues
were harvested for blood chemistry and viral titer analyses.
Tissue harvest and virus titration. OROV-infected mice were sacri-
ficed on days 1, 2, 4, or 6 postinfection. After perfusion (20 ml) with
phosphate-buffered saline (PBS), organs (liver, spleen, kidney, lung,
heart, brain, and spinal cord) were harvested, weighed, homogenized us-
ing zirconia beads in aMagNA Lyser instrument (Roche Life Science) in 1
ml of minimal essential medium (MEM) with 2% heat-inactivated fetal
bovine serum (FBS), and stored at80°C until virus titration. Approxi-
mately 200l of serum from all infected animals was collected and stored
at80°C.
For OROV titration, samples were thawed, clarified by centrifugation
(2,000  g at 4°C for 10 min), and diluted serially prior to infection of
Vero cells in 96-well plates. After 22 to 24 h of infection, the cells were
fixed overnight with 1% paraformaldehyde (PFA) in PBS. Infected cell
foci were detected after incubation with a 1:1,000 dilution of polyclonal
mouse anti-OROV ascites fluid (ATCC VR-1228AF) in a volume of 50l
for 2 h at room temperature. After three washes with 300 l of permeabi-
lization-wash buffer (P-W; PBS, 0.1% saponin, and 0.1% bovine serum
albumin [BSA]), the samples were incubated with 50 l of a 1:2,000 dilu-
tion of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG
(Sigma) for 1 h at room temperature. After three additional washes with
P-W, staining was visualized by the addition of the TrueBlue detection
reagent (KPL), and the spots were analyzed after three washes with 300l
of distilled water with a Biospot counter (Cellular Technology) using Im-
munocapture software. All results were converted into FFU per gram of
tissue, with the exception of serum samples, which were expressed as FFU
per milliliter of serum.
Blood chemistry analysis.Onday 4 or 6 after OROV infection ofWT,
Ifnar/,Mavs/, or Irf3/ Irf7/DKOmice, blood was collected
by intracardiac puncture and serum was isolated. Samples were treated
with -propiolactone (BPL; Sigma Chemical) for 30 min at 37°C to inac-
tivate infectious virus. Blood chemistry analyses were performed using a
Catalyst Dx chemistry analyzer (IDEX Laboratories). Control experi-
ments confirmed that BPL treatment of OROV did not impact chemistry
results (data not shown).
Histology, immunohistochemistry, andTUNELstaining.Mice from
each group (WT, Ifnar/, Mavs/, and Irf3/  Irf7/ DKO) were
infected with OROV, and 4 days later liver and spleen were harvested,
fixed in 4% PFA in PBS for 24 h at 4°C, dehydrated in increasing ethanol
concentrations, and paraffin embedded. Hematoxylin and eosin staining
and terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining of paraffin-embedded tissues were per-
formed by the Digestive Diseases Research Core Center of Washington
University. TUNEL staining was performed using a POD in situ cell death
detection kit (Roche) as described by the manufacturer.
Detection of OROV antigen was performed on 5-m paraffin tissue
sections. Sectionswere deparaffinized, rehydrated, and treated for antigen
retrieval in Tris-borate buffer (pH 7.6) supplemented with 0.05% of a
protease enzyme derived from Streptomyces griseus (Sigma), followed by
incubationwith 0.6%H2O2 inmethanol for 30min to block the activity of
endogenous peroxidases. Sectionswere then blocked for avidin and biotin
with a commercial kit (DakoCytomation biotin blocking system). Subse-
quently, the “Mouse onMouse” (M.O.M.) immunodetection kit was used
according to the manufacturer’s protocol (Vector Laboratories). The sec-
tions were incubated sequentially with M.O.M. mouse immunoglobulin-
blocking reagent and mouse polyclonal anti-OROV or control ascites
fluid (1:100) for 30 min. The binding of primary antibody was detected
usingM.O.M. biotinylated anti-mouse IgG antibody and a 1:300 dilution
of streptavidin-peroxidase ultrasensitive polymer (Sigma). Antigen stain-
ing was visualized using DAB (3,3=-diaminobenzidine) HRP substrate
(Vector) and then counterstained with hematoxylin. Tissue sections were
visualized at 20 and 40 magnification using a Zeiss Axioskop 40 mi-
croscope attached to an AxioCam MRc digital color camera.
Cytokine Bio-Plex assay. On days 4 and 6 after OROV infection of
WT, Ifnar/, Mavs/, and Irf3/  Irf7/ DKO mice, serum was
collected and cytokine levels were analyzed using the Bio-Plex Pro mouse
cytokine assay (Bio-Rad). This platform includes the following cytokines
and chemokines: interleukin 1	 (IL-1	), IL-1, IL-2, IL-3, IL-4, IL-6,
IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, eotaxin (CCL11), granulo-
cyte colony-stimulating factor (G-CSF), granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), IFN-
, KC (CXCL1), monocyte che-
moattractant protein 1 (MCP-1) (CCL-2), MIP-1	 (CCL3), MIP-1
(CCL4), RANTES (CCL5), and tumor necrosis factor alpha (TNF-	).
OROV replication in primary mouse cells. Primary mouse fibro-
blasts (MEFs) from WT, Ifnar/, Mavs/, Mda5/, or Irf3/ 
Irf7/ DKO mice were generated as described previously (47). MEFs
from Rig-I/mice and their WT controls were a gift fromMichael Gale
(Seattle, WA). M and DC cultures were produced as described previ-
ously (52). Bonemarrowwas isolated frommice and cultured for 7 days in
medium supplementedwith 40 ng/mlM-CSF (PeproTech) or 20 ng/ml of
both GM-CSF and IL-4 (PeproTech) to produce M and DCs, respec-
tively. Multistep virus growth curves were performed at a multiplicity of
infection (MOI) of 0.001. The viral titer in the cell-free supernatant was
determined by FFU assay on Vero cells at the following time points after
infection: 0, 1, 4, 12, 24, 36, 48, and 60 h.
Quantification of type I IFN and IFN-stimulated genes (ISGs) in
murine cells.The levels of type I IFN and Ifit1mRNAwere determined by
quantitative reverse transcription-PCR (qRT-PCR). WT, Ifnar/,
Mavs/, or Irf3/  Irf7/ DKO MEFs were infected with OROV at
anMOI of 0.1. Cells were harvested at 1, 4, 12, 24, and 36 h after infection,
and the total RNA was extracted using the RNeasy kit (Qiagen) and
treatedwith TURBODNase (Life Technologies) for 2 h at 37°C. qRT-PCR
for Ifna, Ifnb, Ifit1, and Gapdh mRNA was performed by using one-step
qRT-PCR master mix, with the indicated primers and probes (Table 1).
One-step qRT-PCR also confirmed OROV infection in these cells (data
not shown) by using the indicated primers and probes (Table 1). All
reactions were assembled in a final volume of 25 l with 300 ng of RNA,
1 PrimeTime mix (Integrated DNA Technologies) containing both
primers and probe, and 12.5 l of TaqMan master mix (Applied Biosys-
tems) by using the following cycling algorithm: 48°C for 30 min, 95°C for
10 min, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. All
reactions were normalized to 18S RNA levels by using the eukaryotic 18S
rRNA endogenous control kit (Applied Biosystems) and expressed on a
log2 scale as fold increase over mock (same time point in a noninfected
MEF culture) according to the threshold cycle (CT) method (53).
The levels of secreted IFN- protein in supernatants of OROV-in-
Proenca-Modena et al.
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fected MEFs were measured by a commercial capture enzyme-linked im-
munosorbent assay (ELISA) kit (PBL Laboratories).
OROV replication in U3A and 2fTGH human cells and quantifica-
tion of type I IFN and ISGs. Virus replication and type I IFN mRNA
production were determined by qRT-PCR in 2fTGH-infected (fibrosar-
coma cells) and U3A-infected (2fTGH-derived STAT1-deficient mutant
cells) cells at an MOI of 0.1. Cells were harvested at 1, 4, 12, 24, and 36 h
after infection, and total RNA was obtained as described in the previous
section. The levels of viral RNA were measured by qRT-PCR as described
above and expressed on a log10 scale as genome equivalents/sample after
comparison with a standard curve produced using serial 10-fold dilutions
of OROV RNA. The levels of human IFNB, IFIT1, and GAPDH mRNA
were determined after normalization to 18S levels and expressed on a log2
scale as fold increase over mock, as described in the previous section. All
primers and probes were obtained from Integrated DNA Technologies
(PrimeTime catalogue number for IFNB, Hs.PT.58.39481063.g, for
IFIT1, Hs.PT.56a.20769090.g, and for GAPDH, Hs.PT.39a.22214836).
Statistical analysis. All data were analyzed using Prism software
(GraphPad Software). Kaplan-Meier survival curves were analyzed by the
log rank test, and weight loss values at a given time point were compared
using 2-way analysis of variance (ANOVA). For viral burden analysis, the
log titers were analyzed by the Mann-Whitney test. Type I IFN levels and
qRT-PCR also were compared using 2-way ANOVA. A P value of0.05
indicated statistically significant differences relative to the indicated con-
trol group.
RESULTS
Ifnar/,Mavs/, and Irf3/ Irf7/DKOmice are vulner-
able to lethal OROV infection. Similar to other orthobunyavi-
ruses, in mice, OROV virulence is age dependent, with older ani-
malsmore resistant to lethal infection (22). Injection of 106 FFUof
OROV by a subcutaneous route induced uniformly lethal disease
in newborn C57BL/6WTmice. Three-day-old mice infected with
OROV exhibited 66.6% mortality, whereas 3-, 5-, or 9-week-old
mice did not succumb to infection (data not shown).
Because studies with other arthropod-borne viruses have
shown that age-dependent mortality is determined in part by
changes in innate immune responses (25), we hypothesized that
young adult C57BL/6 mice, which normally are resistant to lethal
OROV infection, might become sensitive if key proteins in the
type I IFN induction and/or signaling pathway were absent. Ac-
cordingly, we evaluated OROV pathogenesis in 6-week-old
Ifnar/, Ifnb/, Mda5/, Mavs/, Irf3/, Irf7/, and
Irf3/  Irf7/ DKO mice. OROV infection of 6-week-old
Ifnar/ mice, which cannot respond to type I IFN, resulted in
100% mortality, with a mean survival time of 5 days and signifi-
cant weight loss (Fig. 1A andC). In contrast, 6-week-oldWTmice
did not show disease signs or weight loss compared to uninfected
animals (Fig. 1B). OROV-infected Ifnar/ mice exhibited leth-
argy and decreased body temperature, especially late in the course
of disease (data not shown). However, signs of neuroinvasive dis-
ease, including limb paralysis, ataxia, seizures, or sustained trem-
ors, were not apparent in OROV-infected Ifnar/ mice. A pro-
tective role for IFN- was supported by studies with 6-week-old
Ifnb/mice infected with OROV (Fig. 1A). Although only a rel-
atively small increase in lethality (17%) was observed in Ifnb/
mice, this attained statistical significance (P 0.02); this pheno-
type correspondedwith greaterweight loss in Ifnb/ animals that
survived OROV challenge or succumbed to lethal infection (Fig.
1F) than in WT mice. Given this difference in disease severity
between Ifnar/ and Ifnb/ mice after OROV infection, it is
likely that other type I IFNs (e.g., IFN-	) restrict OROV in adult
mice.
To determine whether the RLR signaling pathway contributed
to host recognition ofOROVand induction of antiviral responses,
we infected 6-week-old Mda5/ and Mavs/ mice. Mda5/
mice did not succumb to OROV infection (Fig. 1A) or show any
TABLE 1 Primers and probes used for qRT-PCR
Targeta Sequenceb Reference
OROV 83
Fwd 5=-TACCCAGATGCGATCACCAA-3=
Rev 5=-TTGCGTCACCATCATTCCAA-3=
Probe 5=-56-FAM-TGCCTTTGGCTGAGGTAAAGGGCTG-36-TAMSp-3=
Mouse Gapdh 84
Fwd 5=-AATGGTGAAGGTCGGTGTG-3=
Rev 5=-GTGGAGTCATACTGGAACATGTAG-3=
Probe 5=-56-FAM-TGCAAATGG-ZEN-CAGCCCTGGTG-3IABkFQ-3=
Mouse Ifna 84
Fwd 5=-CTTCCACAGGATCACTGTGTACCT-3=
Rev 5=-TTCTGCTCTGACCACCTCCC-3=
Probe 5=-56-FAM-AGAGAGAAGAAACACAGCCCCTGTGCC-36-TAMSp-3=
Mouse Ifnb 52
Fwd 5=-GGCTTCCATCATGAACAACAG-3=
Rev 5=-GTTGATGGAGAGGGCTGTG-3=
Probe 5=-56-FAM-CTGCGTTCCTGCTGTGCTTCTC-36-TAMSp-3=
Mouse Ifit1 52
Fwd 5=-GAGCCAGAAAACCCTGAGTACA-3=
Rev 5=-AGAAATAAAGTTGTCATCTAAATC-3=
Probe 5=-56-FAM-ACTGGCTATGCAGTCGTAGCCTATCGCC-36-TAMSp-3=
a Fwd, forward; Rev, reverse.
b FAM, 6-carboxyfluorescein; TAMsp, 6-carboxytetramethylrhodamine; ZEN, double-quenched probe; 3IABkFQ, 3= Iowa Black FQ.
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disease signs or weight loss compared to WT mice (Fig. 1G). In
comparison, Mavs/ mice were vulnerable to OROV infection,
with a mortality rate of 39% (Fig. 1A), although weight loss dif-
ferences were not observed in the surviving animals (Fig. 1E).
These results indicate that RLR recognition of OROV contributes
to the host defense response in vivo, likely with a dominant effect
of RIG-I. However, we were unable to test OROV infection in
Rig-I/mice, as a Rig-I deficiency on a congenic C57BL/6 back-
ground is embryonic lethal (54).
To assess the impact of the transcription factors downstreamof
RLR signaling and upstream of IFN-	 and IFN- induction, we
infected Irf3/, Irf7/, or Irf3/  Irf7/ DKO mice with
OROV. Whereas Irf3/ or Irf7/ single-KO mice showed no
enhanced mortality (Fig. 1A) or weight loss (Fig. 1H and I) after
OROV inoculation, 54% of Irf3/  Irf7/ DKO mice suc-
cumbed to infection (Fig. 1A), and the surviving animals gained
weight more slowly than uninfected mice (Fig. 1D). Collectively,
these survival and morbidity studies suggest that RLR-mediated
detection (likely RIG-I), MAVS signaling, IRF-3 and IRF-7 tran-
scriptional activity, and type I IFN responses are important com-
ponents of the protective antiviral response against OROV in
adult mice.
OROVreplicatespreferentially in the liver, spleen, andblood
of mice lacking intact type I IFN signaling. To assess how type I
IFN signaling impacts OROV tropism and replication in 6-week-
old mice, we measured viral burden in the serum, liver, spleen,
kidney, lung, heart, brain, and spinal cord on days 1, 2, 4, and 6
after infection of WT, Ifnar/, Mavs/, and Irf3/  Irf7/
FIG 1 Mice with targeted deletions in the IFN induction or signaling pathway are more vulnerable to OROV infection. (A) Survival analysis of 6-week-old mice
after inoculation with 106 PFU of OROV by subcutaneous injection in the footpad: WT (n  33), Ifnar/ (n  25), Ifnb/ (n  23), Mda5/ (n  24),
Mavs/ (n 33), Irf3/ (n 40), Irf7/ (n 25), and Irf3/ Irf7/DKO(n 39)micewere used for survival curves. Data are pooled fromat least three
independent experiments. Asterisks indicate differences that were statistically significant compared toWTmice by the log rank test (**, P 0.01; ***, P 0.001).
(B to I)Weight loss in infected (dead or surviving animals considered separately) anduninfectedmice inWT (n 33 andn 10 for infected anduninfectedmice,
respectively) (B), Ifnar/ (n 25 infected and n 3 uninfected) (C), Irf3/  Irf 7/ DKO (n 14 dead, n 19 survivors, and n 13 uninfected) (D),
Mavs/ (n 13 dead, n 20 survivors, and n 10 uninfected) (E), Ifnb/ (n 4 dead, n 19 survivors, and n 8 uninfected) (F),Mda5/ (n 24 infected
and n 8 uninfected) (G), Irf3/ (n 40 infected and n 15 uninfected) (H), and Irf7/ (n 25 infected and n 9 uninfected) (I) mice. The weight loss
curves were compared using 2-way ANOVA.
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DKO mice. On day 1 after infection, we did not detect infectious
virus in any tissue from the different genotypes.We detected virus
as early as day 2 after infection in the liver and serum of Ifnar/
mice but not in other tissue samples. In comparison, by day 4 after
infection, high levels (1.2  105 to 4.3  108 FFU/g) of OROV
were recovered from the liver and spleen of all Ifnar/ and
Irf3/ Irf7/DKOmice (Fig. 2A and B). Lower (2.5 102 to
4.1  107 FFU/ml or FFU/g) yet significant levels of OROV also
were measured in the serum, kidneys, and lungs of Ifnar/ and
Irf3/  Irf7/ DKO mice on day 4 after infection (Fig. 2C to
E). OROVwas detected in the heart, brain, and spinal cord in only
2 of 15 Ifnar/mice (Fig. 2F toH). InfectiousOROVwas present
in 50% of the Irf3/  Irf7/ DKO mice in the liver and
spleen at day 6 after infection (3.7 103 to 1.5 107 FFU/g).
In comparison to Ifnar/ or Irf3/  Irf7/ DKO mice,
infectious OROV was detected in only a subset of tissues samples
from Mavs/mice, including the liver and spleen on day 4 after
infection. The viral titers in Mavs/ mice generally were lower
(1.5 104 to 5.7 106 FFU/g) (Fig. 2A to H) and cleared by day
6 after infection in the spleen, lung, and serum. In contrast, in the
liver,OROVwas present in 6 of 11Mavs/mice (4 103 to 1.6
106 FFU/g) on day 6. These data suggest that other pathogen rec-
ognition and signaling pathways (e.g., TLR and MyD88) likely
contribute to the induction of type I IFN responses and restriction
of OROV in specific tissues.
Blood chemistry reveals extensive liver injury. To under-
stand the basis for disease in the different KO mice after OROV
infection, we analyzed their blood chemistries. On day 4 after
infection, we observed significant liver injury in Ifnar/,
Mavs/, and Irf3/  Irf7/ DKO mice, as reflected by in-
creased levels of alanine aminotransferase (ALT) (7,307 U/liter,
601 U/liter, and 7,164 U/liter, respectively, compared to 111 U/
liter in infected WT mice; P 0.01) (Fig. 3A) and aspartate ami-
notransferase (AST) (8,387 U/liter, 827 U/liter, and 7,438 U/liter,
respectively, compared to 372 U/liter in infected WT mice; P 
0.01) (Fig. 3B). Liver damage also was suggested by the relative
FIG 2 Tissue viral burden in Ifnar/, Mavs/, and Irf3/  Irf7/ DKO mice infected with OROV. Viral burden after OROV infection of Ifnar/,
Mavs/, and Irf3/ Irf7/DKOmice was measured by focus-forming assay in samples from serum (A), liver (B), spleen (C), kidney (D), lung (E), heart
(F), brain (G), and spinal cord (H). Data points represent individual mice. Bars indicate median values and were obtained from 8 to 15 mice per time point.
Dashed lines represent the limit of sensitivity of the assay. Asterisks indicate statistical significance as judged by theMann-Whitney test (*, P 0.05; **, P 0.01;
***, P 0.001; ****, P 0.0001). The red cross indicates that all OROV-infected Ifnar/ animals were dead at the indicated time point.
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hypoglycemia in Ifnar/, Mavs/, and Irf3/  Irf7/ DKO
mice (glucose [GLU] levels of 50.5 mg/dl, 295.0 mg/dl, and 52.0
mg/dl, respectively) compared to in infectedWTmice (494.0 mg/
dl; P 0.05) (Fig. 3C). In comparison, serum levels of blood urea
nitrogen, creatinine, alkaline phosphatase, and creatine kinase
were similar between infected WT and KO animals (data not
shown). The levels of AST and ALT remained high on day 6 after
infection in the surviving KO mice (Fig. 3B) and reflect acute
hepatic injury, which may be due to direct virus-induced lysis of
hepatocytes, immune-mediated injury, or ischemia.
Pathological and immunohistochemical analysis of the liver
and spleen fromOROV-infectedmice.To define the basis for the
tissue damage associated with OROV infection, we performed
pathological analysis on liver and spleen isolated from WT
Ifnar/, Mavs/, and Irf3/  Irf7/ DKO mice on days 4
and 6 after infection. Necropsy revealed gross macroscopic tissue
damage in the liver of Ifnar/ and Irf3/ Irf7/DKOmice,
which was characterized by visible hemorrhages and tissue discol-
oration in several animals (data not shown). Hematoxylin and
eosin staining of paraffin sections revealed areas of focal cellular
necrosis within the liver of Ifnar/ and Irf3/  Irf7/ DKO
but not in Mavs/ or WT mice by day 4 after OROV infection
(Fig. 4A and B; data not shown); this result correlated with the
higher serum levels of liver enzymes (AST and ALT) in Ifnar/
and Irf3/  Irf7/ DKO mice than in WT mice at this time
point (see Fig. 3A and B). By day 6 after OROV infection, tissue
injury in the liver became apparent in Mavs/ mice (data not
shown). TUNEL staining showed a greater number of dead cells in
the liver and spleen of Ifnar/ and Irf3/  Irf7/ DKOmice
than in WT mice (Fig. 4C and D). Clusters of TUNEL-positive
nuclei were present in the white and red pulp of the spleen (Fig.
4D) in all sections from OROV-infected Ifnar/ and Irf3/ 
Irf7/DKOmice. Immunohistochemistry (IHC)was performed
to determine if tissue damage correlated with viral infection.
OROV antigen-positive cells were apparent on day 4 after infec-
tion in the liver of Ifnar/ and Irf3/  Irf7/ DKO but not
WTmice (Fig. 4E). Small foci of OROV antigen-positive cells also
were detected in the liver ofMavs/mice on day 6 after infection
(data not shown). Based on cellular morphology and viral antigen
staining, hepatocytes appear to be a major target of OROV infec-
tion. In contrast, in the spleen, OROV antigen-positive cells were
observed only in sections of Ifnar/mice, in both the white and
red pulp (Fig. 4F).
Hypercytokinemia in OROV-infected mice. To define addi-
tional possible mechanisms of tissue injury, we measured serum
levels of 23 pro- and anti-inflammatory cytokines and chemo-
kines on days 4 and 6 after OROV infection using Bio-Plex assays
(Fig. 5 andTable 2). Althoughwe did not observe elevated levels of
inflammasome-generated (e.g., IL-1) or vasoactive (e.g.,
TNF-	) cytokines in the infected KO mice, a marked increase in
several proinflammatory cytokines (IL-6, IL-12p40, and G-CSF)
on day 4 (Ifnar/ and Irf3/  Irf7/ DKO) and day 6
(Mavs/) after OROV infectionwas apparent (Fig. 5A to C). The
increased levels of these proinflammatory cytokines (e.g., IL-6)
suggested a mechanism of production that was independent of
MAVS, which contrasts with prior studies with flaviviruses (51).
In comparison, the levels of IL-2, IL-3, IL-5, IL-10, IL-13, and
IL-17A were not increased in the KO animals after OROV infec-
tion. However, higher levels of several (e.g., MCP-1, MIP-1	, KC,
and RANTES) but not all (eotaxin andMIP-1) chemokines were
observed in OROV-infected KOmice than inWTmice (Fig. 5E to
H and Table 2). Although some cytokine and chemokine levels
were elevated in KO mice after OROV infection, the relatively
minor change in IL-1 and TNF-	 levels, coupled with the ab-
sence of renal damage, suggests that the disease pathogenesis oc-
curs independently of a generalized cytokine storm.
OROV replication is enhanced in primary cell cultures with
defects in IFN inductionor signaling.Tobegin to determine how
the components of the type I IFN induction and signaling pathway
affected OROV infection in specific cell types, we performedmul-
tistep growth analysis in MEFs, DCs, and M derived from WT
mice and Mda5/, Rig-I/, Ifnar/, Mavs/, and Irf3/ 
Irf7/ DKO mice. In MEFs, deletion of either RIG-I or MDA-5
did not affect OROV infection substantively compared to titers
observed in WT cells (Fig. 6A). However, OROV replicated to
higher levels (2.3- to 4.2-fold,P 0.05) in Ifnar/,Mavs/, and
Irf3/  Irf7/ DKO MEFs than in WT MEFs at 24 and 60 h
after infection (Fig. 6B). In comparison, OROV replication was
observed in bone marrow-derived DCs from Ifnar/, Mavs/,
and Irf3/ Irf7/DKOmice but not fromWTmice (Fig. 6C).
For M, productive OROV infection was apparent only in cells
derived from Ifnar/ mice (Fig. 6D). These results suggest that
FIG 3 Blood chemistry reveals extensive liver injury after OROV infection. Alanine aminotransferase (ALT) (A), aspartate aminotransferase (AST) (B), and
glucose (GLU) (C) levels were measured from serum samples of WT and Ifnar/,Mavs/, and Irf3/ Irf7/mice (n 8 to 13 for each group) obtained
4 and 6 days after infectionwith 106 FFUofOROV.Data points represent individualmice and are pooled from three independent experiments. Asterisks indicate
statistical significance as judged by the Mann-Whitney test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). The red dotted lines represent the mean
values from three mock-infected naive mice. In the mouse phenome database (Jackson Laboratory), the mean ALT, AST, and GLU levels in serum of 6- to
8-week-old C57BL/6J mice were 23.6 (7.6), 94.0 (48.9), and 176 (31.4), respectively. A red cross indicates that all OROV-infected Ifnar/ animals were
dead at the indicated time point.
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while specific components of the IFN induction and signaling
pathways restrict OROV in all cell types, their inhibitory effect is
more dominant in myeloid cells, at least in culture.
OROV induces type I IFN production in mouse cells. Al-
though severalmembers of theOrthobunyavirus genera, including
LACV, SBV, and BUNV, inhibit induction of type I IFN (33, 34,
55), we hypothesized that OROV might lack this activity in mu-
rine cells, which could explain its failure to cause disease in WT
immunocompetentmice or replicate efficiently in someof theWT
primary cells. To test this hypothesis, we infected WT, Ifnar/,
Mavs/, and Irf3/  Irf7/ DKO MEFs with OROV and
measured Ifna and Ifnb mRNA levels by qRT-PCR after 1, 4, 12,
24, and 36 h. In parallel, we measured mRNA levels of Ifit1, a
strongly induced ISG, and Gapdh; the latter gene serves as a
control for possible virus-induced host transcriptional shutoff
(Fig. 7A). We infected WTMEFs, as a positive control, with West
Nile virus (WNV), an encephalitic flavivirus that potently induces
type I IFN (52). In contrast to that seen with BUNV in either
murine or human 293 cells (37), OROV infection did not inhibit
type I IFN or ISG induction in WT MEFs, as induction of Ifna,
Ifnb, and Ifit1mRNAwas observed within 4 h of infection (Fig. 7B
to D). The production of these mRNA, however, was delayed and
blunted inMavs/ and Irf3/ Irf7/DKOMEFs (Fig. 7B to
D), indicating that RLR signaling through IRF-3 and IRF-7 had a
dominant effect on IFN and ISG induction. Consistent with this,
we did not detect IFN- protein by ELISA in the supernatants of
Mavs/ or Irf3/  Irf7/ DKO MEFs, whereas high levels
were observed inOROV-infectedWT and Ifnar/ cells (Fig. 7E).
InMavs/ but not Irf3/ Irf7/DKO cells, Ifit1mRNA still
accumulated, suggesting an RLR-independent pathway of induc-
FIG 4 Tissue analysis of OROV-infected WT, Ifnar/, and Irf3/  Irf7/ DKOmice. (A and B) Histological (hematoxylin and eosin staining) analysis of
the liver (A) and spleen (B) from uninfected WT mice and OROV-infected WT, Ifnar/, or Irf3/  Irf7/ DKO mice. Representative images (20
magnification) were taken 4 days after OROV infection from 3 mice of each group. (C and D) Representative images of TUNEL staining of liver (C) and spleen
(D) of uninfected WT and infected WT, Ifnar/, and Irf3/  Irf7/ DKO mice were taken 4 days after OROV infection from 3 mice from each group. (E
and F) Detection of OROV antigen in liver (E) and spleen (F) of uninfectedWT and infectedWT, Ifnar/, and Irf3/ Irf7/DKOmice 4 days after virus
infection. Representative images (taken at 20magnification but decreased by 20%of their original size to fit)were obtained from threemice of each group. Inset
images show a higher magnification image (taken at 40magnification) and correspond to the region marked by the arrow. Scale bar, 100 m.
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tion, possibly through TLRs (e.g., TLR3). Ifit1 mRNA levels were
abolished in OROV-infected Ifnar/MEFs (Fig. 7D) despite the
increased level of infection, suggesting that the IFN-independent
(e.g., IRF3-dependent [56]) pathway of ISG induction could not
compensate for the loss of type I IFN signaling. These results in-
dicate that OROV does not antagonize type I IFN production or
signaling efficiently in mouse fibroblasts.
In comparison, the production of IFNA, IFNB, and IFIT1
mRNAs after OROV infection was blunted in both 2fTGH and
U3A (a 2fTGH-derived cell lacking STAT1) human fibrosarcoma
cells relative to GAPDH expression or WNV infection (Fig. 7F to
H; data not shown). Consistent with this attenuated IFN response,
OROV replicated equally well in both cells lines (Fig. 7I). In par-
ticular, low levels of the ISG IFIT1 were observed in OROV-in-
fected cells, which suggests a virus-mediated defect in IFN-depen-
dent or independent induction pathways. Thus, OROVappears to
antagonize type I IFN production or signaling more efficiently in
human cells than in mouse cells, which could explain why IFN
induction and signaling are key restriction components in the
murine model.
Type I IFNsignaling innonmyeloid cells likely contributes to
defense against infection by OROV. As a deficiency of IFNAR
signaling resulted in enhancedOROV infection ofmyeloid cells in
culture, we evaluated its contribution to pathogenesis by infecting
LysM Cre Ifnarf/f, CD11c Cre Ifnarf/f, and Cre Ifnarf/f mice,
which selectively delete IFNAR expression on M, monocytes,
and granulocytes (LysM) or CD11cDCs (57, 58). Unexpectedly,
LysM Cre Ifnarf/f and CD11c Cre Ifnarf/f clinically were not
more vulnerable to OROV infection; mortality rates and weight
loss were similar to those for OROV-infected Cre Ifnarf/f or WT
mice (Fig. 8A and B). As observed in WT mice (see Fig. 2), infec-
tious OROV was not detected in any tissue from LysM Cre
Ifnarf/f, CD11c Cre Ifnarf/f, or Cre Ifnarf/f mice on day 4 after
infection by focus-forming assay (data not shown). However, us-
ing amore sensitive qRT-PCR assay that detects viral mRNAs and
genomes, higher levels of OROV RNA were measured in the
spleen of LysM Cre Ifnarf/f (P 0.004) and CD11c Cre Ifnarf/f
(P 0.05) mice than Cre Ifnarf/f or WTmice (Fig. 8C), suggest-
ing that the deletion of IFNAR expression in myeloid cells facili-
tated OROV replication in vivo, but this was not sufficient to
change the clinical outcome. Indeed, the levels of OROV RNA in
the liver and serumwere similar among all groups of animals (Fig.
8C and D). By inference, these results suggest that type I IFN
signaling in nonmyeloid cells contributes to restricting OROV
pathogenesis in vivo.
To assess whether myeloid cell types have a significant role in
restricting infection by other orthobunyaviruses in vivo, we in-
fected LysM Cre Ifnarf/f, CD11c Cre Ifnarf/f, Cre Ifnarf/f,
Ifnar/, and WT mice with 105 or 106 FFU of LACV. Similar to
results reported previously (34, 36, 37), uniform and rapid lethal-
ity was observed after LACV infection of Ifnar/ mice lacking
type I IFN signaling in all cell types (Fig. 8E and F). Analogous to
the results seen with OROV, CD11c Cre Ifnarf/f mice did not
show substantially enhanced lethality after LACV infection com-
pared to Cre Ifnarf/f and WT mice at either LACV dose (Fig. 8E
and F). A significant weight loss in LACV-infected CD11c Cre
Ifnarf/f mice occurred late, on days 10 and 12, and only after infec-
tion with 106 FFU of LACV (Fig. 8G and H). Unexpectedly, LysM
Cre Ifnarf/f mice were more resistant to lethal LACV infection
thanWT or Cre Ifnarf/f mice (Fig. 8F), suggesting that type I IFN
signaling in M, monocytes, or granulocytes has a role in the
pathogenesis induced by LACV. Independent of the differences in
outcome, these results suggest that type I IFN signaling on non-
myeloid cells contributes to controlling infection of different or-
thobunyaviruses.
To corroborate the importance of type I IFN signaling in non-
FIG5 Serum cytokine and chemokine levels inOROV-infectedmice.WT, Ifnar/, Irf3/ Irf7/, andMavs/micewere infectedwith 106 FFUofOROV.
Four or 6 days later, serum was collected and the concentrations of the indicated cytokines (A to D) or chemokines (E to H) were determined by Bio-Plex assay.
Data points represent individual mice, and the bars indicate the mean values  standard deviations (SD) for each group. A red cross indicates that all
OROV-infected Ifnar/ animals were dead at the indicated time point. Asterisks indicate statistical significance compared to serum from OROV-infectedWT
mice as judged by theMann-Whitney test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). The red dotted lines represent themean values from three
mock-infected mice for each analyzed cytokine.
Proenca-Modena et al.
4728 jvi.asm.org May 2015 Volume 89 Number 9Journal of Virology
TABLE 2 Serum cytokine and chemokine levels after OROV infectiona
Cytokine Genotype
Day 4 p.i. Day 6 p.i.
pg/ml (SD) P pg/ml (SD) P
IL-1	 WT 1.3 (1.6) 2.6 (2.3)
Ifnar/ 5.3 (8.3) 0.93
Irf3/  Irf7/ 10.6 (11.5) 0.08 0.6 (1.4) 0.05
Mavs/ 0 (0) 0.03 5.4 (7.8) 0.96
IL-1 WT 189.4 (44.2) 208.2 (53.4)
Ifnar/ 266.0 (179.8) 0.54
Irf3/  Irf7/ 205.7 (135.5) 0.99 109.1 (101.3) 0.04
Mavs/ 123.5 (95.1) 0.07 88.9 (101.5) 0.02
IL-2 WT 25.0 (14.6) 26.9 (21.9)
Ifnar/ 18.9 (11.3) 0.55
Irf3/  Irf7/ 20.9 (14.1) 0.51 14.9 (11.9) 0.50
Mavs/ 16.6 (12.8) 0.05 28.3 (12.7) 0.22
IL-3 WT 12.8 (11.9) 16.5 (13.3)
Ifnar/ 5.13 (7.19) 0.15
Irf3/  Irf7/ 8.6 (9.9) 0.68 4.6 (7.1) 0.09
Mavs/ 3.6 (3.3) 0.17 2.0 (3.1) 0.008
IL-4 WT 6.9 (8.4) 8.6 (9.1)
Ifnar/ 2.5 (3.9) 0.30
Irf3/  Irf7/ 3.0 (5.7) 0.20 2.1 (5.0) 0.32
Mavs/ 0 (0) 0.06 0 (0) 0.03
IL-5 WT 14.3 (7.5) 16.2 (7.1)
Ifnar/ 10.2 (3.1) 0.15
Irf3/  Irf7/ 6.2 (4.2) 0.004 9.2 (10.2) 0.17
Mavs/ 8.8 (5.8) 0.15 3.5 (5.8) 0.002
IL-6 WT 4.2 (1.5) 5.9 (2.9)
Ifnar/ 1,048 (1,921) 0.00008
Irf3/  Irf7/ 606 (1,055) 0.0001 56.8 (107.4) 0.76
Mavs/ 5.8 (4.8) 0.64 146.1 (279.1) 0.0002
IL-9 WT 108.6 (115.4) 116.5 (131.9)
Ifnar/ 337.9 (410.3) 0.36
Irf3/  Irf7/ 159.7 (282.9) 0.68 0 (0) 0.03
Mavs/ 96.3 (167.6) 0.64 325.6 (425.8) 0.45
IL-10 WT 22.8 (16.3) 25.6 (14.1)
Ifnar/ 23.8 (14.6) 0.75
Irf3/  Irf7/ 31.6 (35.1) 0.63 10.9 (6.9) 0.01
Mavs/ 17.4 (17.0) 0.31 16.7 (15.0) 0.18
IL-12 (p40) WT 42.8 (30.9) 35.4 (17.6)
Ifnar/ 341.7 (164.1) 0.0001
Irf3/  Irf7/ 338.7 (248.8) 0.0001 32.6 (25.1) 0.58
Mavs/ 86.5 (79.2) 0.09 69.7 (77.6) 0.35
IL-12 (p70) WT 18.6 (12.2) 21.3 (8.7)
Ifnar/ 74.5 (93.6) 0.51
Irf3/  Irf7/ 33.8 (31.2) 0.81 13.3 (11.9) 0.11
Mavs/ 14.6 (11.6) 0.55 21.8 (29.0) 0.17
IL-13 WT 31.6 (26.3) 47.6 (52.2)
Ifnar/ 30.3 (31.9) 0.97
Irf3/  Irf7/ 47.2 (61.9) 0.72 10.19 (15.0) 0.04
Mavs/ 14.0 (25.4) 0.052 12.3 (13.3) 0.03
(Continued on following page)
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myeloid cells inOROVpathogenesis, reciprocal bonemarrow chi-
mera and infection studies were performed. We adoptively trans-
ferred WT or Ifnar/ bone marrow cells into sublethally
irradiated 4-week-old Ifnar/ or WT recipient mice (Fig. 9A).
Eight weeks later, the reconstitution of donor immune cell popu-
lations in blood was confirmed in recipient mice by flow cytom-
etry (Fig. 9B). All recipient animals were infected with OROV and
4 days later were analyzed. WT recipient animals receiving donor
TABLE 2 (Continued)
Cytokine Genotype
Day 4 p.i. Day 6 p.i.
pg/ml (SD) P pg/ml (SD) P
IL-17 WT 7.7 (5.1) 8.7 (6.6)
Ifnar/ 5.3 (5.9) 0.15
Irf3/  Irf7/ 5.0 (4.7) 0.12 5.1 (4.3) 0.28
Mavs/ 2.5 (2.1) 0.02 2.4 (1.6) 0.07
Eotaxin WT 422.5 (287.0) 478.5 (230.7)
Ifnar/ 451.5 (462.0) 0.84
Irf3/  Irf7/ 344.2 (292.9) 0.42 178.5 (170.8) 0.005
Mavs/ 145.1 (189.2) 0.03 180.2 (206.0) 0.01
G-CSF WT 15.8 (5.2) 13.6 (5.5)
Ifnar/ 3,064 (4,307) 0.0004
Irf3/  Irf7/ 3,000 (3,767) 0.0001 106.7 (146.5) 0.09
Mavs/ 10.8 (8.2) 0.15 1,307 (2,543) 0.03
GM-CSF WT 70.8 (26.6) 74.8 (29.3)
Ifnar/ 86.5 (32.8) 0.12
Irf3/  Irf7/ 63.5 (23.9) 0.43 57.6 (39.7) 0.23
Mavs/ 43.9 (19.1) 0.06 22.0 (28.3) 0.03
IFN-
 WT 2.5 (2.1) 2.8 (1.4)
Ifnar/ 34.2 (22.8) 0.0004
Irf3/  Irf7/ 4.9 (3.9) 0.11 3.9 (3.7) 0.94
Mavs/ 1.5 (1.5) 0.29 6.4 (5.1) 0.10
KC WT 28.7 (9.5) 35.3 (18.7)
Ifnar/ 384.2 (212.1) 0.0008
Irf3/  Irf7/ 285.5 (196.0) 0.0001 28.5 (24.6) 0.23
Mavs/ 61.6 (59.9) 0.79 87.6 (48.8) 0.008
MCP-1 WT 156.1 (113.0) 202.0 (132.8)
Ifnar/ 716.6 (267.5) 0.0003
Irf3/  Irf7/ 902.8 (786.5) 0.0026 195.2 (221.3) 0.39
Mavs/ 335.5 (435.0) 0.98 946.6 (903.8) 0.0043
MIP-1	 WT 1.6 (1.5) 2.1 (1.9)
Ifnar/ 8.8 (6.6) 0.004
Irf3/  Irf7/ 5.8 (3.6) 0.0001 5.6 (5.1) 0.13
Mavs/ 2.7 (5.2) 0.52 6.6 (6.8) 0.12
MIP-1 WT 36.6 (22.8) 45.2 (20.4)
Ifnar/ 35.0 (24.0) 0.91
Irf3/  Irf7/ 23.7 (12.3) 0.21 38.8 (36.6) 0.71
Mavs/ 31.5 (16.2) 0.69 18.5 (16.9) 0.03
RANTES WT 14.5 (5.8) 14.1 (5.1)
Ifnar/ 85.6 (52.3) 0.0008
Irf3/  Irf7/ 50.9 (34.5) 0.0001 12.6 (7.6) 0.64
Mavs/ 15.3 (17.1) 0.30 31.6 (19.8) 0.04
TNF-	 WT 276.4 (193.8) 334.2 (182.7)
Ifnar/ 198.4 (117.9) 0.36
Irf3/  Irf7/ 179.1 (113.4) 0.20 145.2 (101.3) 0.05
Mavs/ 155.0 (157.2) 0.17 137.3 (114.5) 0.04
a The indicated strains of mice were infected with OROV. Serum was collected on days 4 and 6 postinfection (p.i.), and cytokines and chemokines were measured by Bio-Plex array.
Data represent the means (SD) in pg/ml from 8 to 12 mice per group. Statistical significance was determined using the Mann-Whitney test, and P values were obtained after
comparison to infected WT mice.
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bone marrow cells from either WT or Ifnar/ mice showed no
macroscopic evidence of liver injury. Consistent with this obser-
vation, these recipient animals had only mildly elevated serum
transaminases (AST and ALT), normal glucose levels in serum,
and little evidence of OROV infection in the liver or spleen (Fig.
9C and D). In contrast, OROV-infected Ifnar/ mice that had
received WT donor bone marrow sustained liver injury that was
equivalent to that in unmanipulated Ifnar/mice,withmarkedly
elevated AST and ALT levels, hypoglycemia, and high levels of
OROV infection. These studies support a protective role of IFNAR
signaling in radio-resistant nonmyeloid cells during OROV infec-
tion.
DISCUSSION
In this study, we evaluated the mechanisms of innate immune
control of OROV, an emerging insect-transmitted orthobunyavi-
rus of global concern. Our experiments suggest that pathogen rec-
ognition by RLR familymembers, activation ofMAVS, IRF-3, and
IRF-7, and production of type I IFN help to orchestrate control of
OROV replication in mice. As evidence of this, although 6-week-
old WT C57BL/6 mice were resistant to OROV infection and did
not sustain appreciable infectious titers in their organs, a high
proportion of Ifnar/, Mavs/, and Irf3/  Irf7/ DKO
mice succumbed to lethal infection by a subcutaneous injection
route and developed high levels of virus in the liver, spleen, and
blood.
Our results demonstrate that an IFN-induced antiviral state
againstOROVwas triggered downstreamofMAVS activation and
IRF-3- and IRF-7-mediated transcription, although some
Mavs/ and Irf3/  Irf7/ DKO mice survived and cleared
the virus infection. It is likely that both IFN-	 and IFN- contrib-
ute to protection against OROV infection, since only a small pro-
portion of Ifnb/mice succumbed to viral infection, whereas all
Ifnar/ mice died rapidly. Analogously, Ifnb/ mice exhibited
an intermediate survival phenotypewhen infectedwith the related
LACV (35) or unrelated WNV (59). A recent study on LACV
showed that activation of MAVS led to upregulation of the adap-
tor protein SARM1 and increased neuronal death via oxidative
stress and mitochondrial damage (40). In that study, Mavs/
mice showed decreased lethality compared to that of WT mice,
although viral yields in the brain were unchanged. Our results
differ in that Mavs/ mice were more vulnerable to OROV in-
fection and sustained higher titers in the liver than WT mice.
Although direct comparative experiments are warranted, the dis-
parity in the MAVS-dependent phenotype between the two stud-
ies could reflect experimental variables, including the age of the
mice (3 versus 6 weeks old), the route of inoculation (intraperito-
neal versus subcutaneous), and the input dose (103 versus 106
FFU) or inherent differences in pathogenicity and tropism of
OROV and LACV.
IRF-3 and IRF-7 are transcription factors that regulate expres-
sion of type I IFN and ISGs (56, 60). Although IRF-3 is expressed
constitutively in many cell types, apart from a subset of cells, in-
cluding plasmacytoid DCs, IRF-7 expression is induced by IRF-3
or IFNAR signaling (61). The nonredundant roles of IRF-3 and
IRF-7 have been documented in pathogenesis studies with other
viruses (47, 62). Consistent with this, we observed no lethality of
Irf3/ or Irf7/ single-KOmice after OROV infection, whereas
50% of Irf3/  Irf7/ DKO mice succumbed to infection
and exhibited greater viral burden. Nonetheless, the Irf3/ 
Irf7/ DKO mice did not phenocopy Ifnar/ mice. OROV
also replicated to higher levels in Ifnar/ DCs and M than in
Irf3/ Irf7/ cells. These data suggest that other transcription
factors likely contribute to type I IFN induction after OROV in-
fection. IRF-1 and IRF-5 are candidate factors, as they have been
shown to regulate type I IFN responses against viruses under some
circumstances (52, 63–66).
In our immunocompromised mouse models of OROV infec-
tion, we observed hepatic injury and necrosis that likely caused
lethal disease, which was not observed in WT mice. This disease
FIG 6 OROV replication in primaryMEFs, DCs, andM. (A and B) Kinetics of OROV replication inWT, Ifnar/,Mavs/, and Irf3/ Irf7/MEFs (A)
or Rig-I/, Rig-I/, and MDA5/ MEFs (B) after infection at an MOI of 0.001. Supernatants were harvested at the indicated times for titration by
focus-forming assay. (C and D) Kinetics of OROV replication in DCs (C) and M (D) derived fromWT, Ifnar/,Mavs/, and Irf3/  Irf7/mice after
infection at anMOI of 0.001. The data represent themeans SD from three independent experiments performed in triplicate. All KO cell groupswere compared
toWT by two-way ANOVA, and asterisks indicate statistical significance (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). The dotted line represents
the limit of detection of the assay.
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manifested histologically as TUNEL hepatocytes and by the high
levels of liver transaminases and low level of glucose in serum. In
humans, this extensive degree of liver injury is not typical, al-
though elevated liver transaminases in serum of patients with
OROV fever have been reported (12). Although some aspects of
OROV disease in the KO mice do not clearly parallel human
infection, the development of subcutaneous infection mouse
models of OROV likely will be useful in monitoring effects on
viral replication in the context of future preclinical testing of
therapeutics, akin to studies with the unrelated dengue virus
(DENV), which also replicates poorly in WT mice (reviewed in
reference 67).
Because our histopathological and blood chemistry studies
showed massive liver damage after OROV infection of immuno-
compromised mice, we hypothesized this might be due to sepsis
and cytokine storm, as we observed previously with the flavivirus
WNV (51). Although we detected an elevation in the levels of
several cytokines and chemokines (e.g., IL-6, IL-12p40, G-CSF,
KC, MCP-1, MIP-1	, and RANTES) in Ifnar/, Mavs/, and
Irf3/  Irf7/ DKO mice on days 4 and 6 after OROV infec-
tion, the vasoactive cytokines TNF-	 and IL-1 were within the
normal range. Also inconsistent with a cytokine storm scenario
and sepsis physiology, we failed to observe significant renal dam-
age, as judged by normal blood urea nitrogen and serum creati-
nine values. Together with our viral burden and immunohisto-
chemical analyses, it seems more likely that the liver damage in
OROV-infected Ifnar/, Mavs/, and Irf3/  Irf7/ DKO
mice was due to the direct cytopathic effects of the virus in hepa-
tocytes. Alternatively, although further study is necessary, im-
mune cell targeting of virally infected cells by natural killer or
cytotoxic T cells could contribute to acute liver damage. The eti-
ology of liver damage and its role in orthobunyavirus pathogenesis
remain to be completely understood, although OROV andMelao
virus (MELV) infection directly infect the liver in hamsters (21,
FIG 7 OROV efficiently induces type I IFN production and ISGs inmurine but not in human cells. (A to D)MEFs fromWT, Ifnar/,Mavs/, and Irf3/
Irf7/mice were infected with OROV at anMOI of 0.1 or mock infected. At 1, 4, 12, or 36 h after infection, the relative expression levels ofGapdh (A), Ifna (B),
Ifnb (C), and Ifit1 (D)mRNAwere determined by qRT-PCR. Gene expression was normalized to 18S rRNA and is displayed as the fold increase compared to the
mock-infected cells on a log2 scale. Data represent the averages from three independent experiments performed in triplicate and are expressed as themeans SD.
(E) MEFs from WT, Ifnar/, Mavs/, and Irf3/  Irf7/ mice were infected with OROV at an MOI of 0.1. At 1, 4, 12, 36, and 48 h after infection, the
accumulation of IFN- protein in the supernatant was determined by ELISA. The results are expressed in pg/ml after plotting the optical densities using a
4-parameter fit for the standard curve run in the same plate. The data represent the means SD from two independent experiments performed in triplicate. (F
to H) 2fTGH and U3A human cells were infected with OROV at anMOI of 0.1 or mock infected. At 1, 4, 12, or 36 h after infection, the relative expression levels
ofGAPDH (F), IFNB (G), and IFIT1 (H)mRNAwere determined by qRT-PCR.Gene expressionwas normalized to 18S rRNAand is displayed as the fold increase
compared to the mock-infected cells on a log2 scale. (I) Kinetics of OROV replication in 2fTGH and U3A human cells after infection at anMOI of 0.1. The cells
were lysed and harvested at the indicated times for RNA extraction and qRT-PCR. The data represent the means  SD from three independent experiments
performed in triplicate. In this figure, asterisks indicate statistical significance (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001), and the dotted line
represents the limit of detection of the assay.
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68). Additional pathological mechanisms may contribute, as in-
fection of mice with Caraparu virus (CARV), a member of group
C of the Bunyaviridae family, induces acute oxidative stress-de-
pendent hepatitis, with increased serum levels of AST and ALT
(69).
Myeloid cell-dependent IFNAR signaling is essential for re-
stricting pathogenesis of some (e.g., WNV, DENV, and mouse
hepatitis viruses) (51, 70, 71) but not all (e.g., chikungunya virus)
viruses (72). Somewhat unexpectedly, CD11c Cre Ifnarf/f and
LysM Cre Ifnarf/f did not succumb to infection with 106 FFU of
OROV or 105 FFU of LACV, suggesting that IFNAR signaling by
nonmyeloid cell subtypes has a dominant role in restricting infec-
tion by these orthobunyaviruses. Bone marrow chimera studies
revealed that IFNAR signaling in radio-resistant cells helps to re-
strict OROV infection and injury in the liver. It remains possible
that IFNAR signaling in selected radio-resistant myeloid cell sub-
sets (e.g., resident tissue macrophages) in vivo contributes to con-
trol of OROV infection. Moreover, IFN signaling in myeloid cells
likely has some role in restricting orthobunyaviruses, as bonemar-
row-derivedM and DCs fromWTmice were relatively resistant
to OROV infection, whereas cells from Ifnar/ mice were sus-
ceptible. Consistent with this data, increased levels of OROVRNA
were detected in the spleen of CD11c Cre Ifnarf/f and LysMCre
Ifnarf/f mice, and infection with LACVwas associated with greater
weight loss in CD11c Cre Ifnarf/f mice. Indeed, a recent study
demonstrated that myeloid dendritic cells are critical for the type
I IFN response and protection to LACV in adult mice (73). Dif-
ferences on routes of infection (subcutaneous versus intraperito-
neal) and age of animals (8 versus 6 weeks old) may explain the
disparity in mortality rates between the two studies in CD11c
Cre Ifnarf/f mice after LACV infection.
OROV is a zoonotic virus that circulates in vertebrate animals
in South America, including sloths and monkeys. The ability of
OROV to infect and replicate in wild rodents remains uncertain,
but the seroprevalence rate is low (12). Productive infection by
OROV in a mammalian host likely depends on several factors,
including its ability to evade the innate immune response. Mem-
bers of the Bunyaviridae family possess several mechanisms to
FIG 8 LysM Cre Ifnarf/f and CD11c Cre Ifnarf/f are not more vulnerable to OROV and LACV infection. (A) Survival analysis of 5- to 6-week-old mice after
inoculation with 106 FFU of OROV by footpad injection: CD11c Cre Ifnarf/f (n 30), LysM Cre Ifnarf/f (n 25), and Cre Ifnarf/f (n 31) mice were used
to construct survival curves. Data are pooled from at least three independent experiments. (B) Weight loss in CD11c Cre Ifnarf/f (n 30), LysM Cre Ifnarf/f
(n 25), and Cre Ifnarf/f (n 31) mice. The weight loss curves were compared at a given time point using 2-way ANOVA. (C andD) Quantification of OROV
RNA by qRT-PCR in the liver (C), spleen (C), and serum (D) fromWT, CD11c Cre Ifnarf/f, LysM Cre Ifnarf/f, and Cre Ifnarf/f mice at 4 days after infection.
A scatter plot of the data is shown, with each point representing a single animal. The bars indicate median values and were obtained from 10mice per group. The
dotted line represents the limit of detection of the assay. Groups were compared to the WT by the Mann-Whitney test; asterisks indicate statistically significant
differences (*, P 0.05; **, P 0.01). Note, OROV RNA was detected in the serum, spleen, and liver of WTmice by qRT-PCR, as this assay was more sensitive
than infectious virus titration (Fig. 2) or IHC (Fig. 4). (E and F) Survival analysis of 8-week-old mice after inoculation with 105 FFU (n 23 for WT, n 5 for
Ifnar/, n 25 for LysM Cre Ifnarf/f, n 12 for CD11c Cre Ifnarf/f, and n 8 for Cre Ifnarf/f) (E) or 106 FFU (n 21 for WT, n 5 for Ifnar/, n 23
for LysM Cre Ifnarf/f, n  16 for CD11c Cre Ifnarf/f, and n  13 for Cre Ifnarf/f) (F) of LACV by footpad injection. (G and H) Weight loss analysis of
8-week-old mice after inoculation with 105 FFU (G) or 106 FFU (H) of LACV by footpad injection in the same mice. Data are pooled from at least three
independent experiments. Survival curves were analyzed by the log rank test, and weight loss values were compared by 2-way ANOVA. Asterisks indicate
differences that were statistically significant compared to WT animals with the same viral dose (*, P 0.05).
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FIG 9 A deficiency of IFNAR expression on radio-resistant cells determines OROV pathogenesis. (A) Bone marrow cells from C57BL/6 WT or Ifnar/mice
were transferred adoptively (107 cells per recipient animal) to 800-cGy-irradiated 4-week-oldWTor Ifnar/mice (WT¡WT,WT¡Ifnar/, Ifnar/¡WT).
After validation of donor immune cell reconstitution (B), recipient animals were infected with 106 FFU of OROV. Four days later, serum, spleen, and liver were
harvested for blood chemistry and viral titer analyses. Results were compared to data obtained in parallel experiments with OROV-infected unmanipulated
Ifnar/mice. (C) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and glucose (GLU) levels were measured from serum of recipient WT
and Ifnar/mice 4 days after OROV infection. Data points represent individual mice. Data are pooled from two independent experiments, and the asterisks
indicate statistical significance as judged by theMann-Whitney test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). (D) Quantification of OROV in
the liver, spleen, brain, and serum from recipientWT and Ifnar/mice at 4 days after infection. A scatter plot of the data is shown, with each point representing
a single animal. The bars indicate median values and were obtained from 5 to 14 mice per group. The dotted line represents the limit of detection of the assay.
Groups were compared by the Mann-Whitney test; asterisks indicate statistically significant differences (**, P 0.01; ***, P 0.001).
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antagonize the type I IFN and innate immune response pathways,
primarily through the actions of N-terminal domains in the L
protein or via their NSs protein. The L gene of CCHFV encodes an
ovarian tumor (OUT) domain-containing viral protease that hy-
drolyzes ubiquitin and ISG15 from cellular target proteins, which
leads to inhibition of NF-B-dependent signaling and loss of an-
tiviral effects of ISG15 (74). The NSs genes of orthobunyaviruses
reportedly induce mammalian cell protein shutoff (33, 75), sup-
pression of RNA interference (55), and inhibition of IFNB tran-
scription and ISG production (33–35). AlthoughNSs proteins are
not essential for orthobunyavirus growth in tissue culture (re-
viewed in reference 76), they contribute to pathogenesis, as their
deletion attenuates infection in mice, as seen for Akabane virus,
BUNV, and LACV (33, 35, 37, 77). The recent development of an
artificial minigenome system for OROV (78) will help to address
which genes (L, NSs, or other genes) antagonize the type I IFN
pathway to promote infection.
Our data suggest that OROV did not inhibit type I IFN pro-
duction efficiently inmouse cells and, accordingly, virus infection
was greater in cells deficient in IFN induction or signaling. Corre-
spondingly, in WT mice, OROV infection was abortive, whereas
high levels of replication and disease were sustained in Ifnar/ or
Irf3/  Irf7/ animals. In contrast, at least in the two human
cell lines that we tested, the induction of type I IFN or ISGs was
diminished. One possible explanation for our findings, which re-
quires confirmation, is a species-specific immune antagonism ac-
tivity of OROV NSs (or L), which blocks human but not mouse
IFN responses. This concept might explain the species barrier of
OROV in immunocompetent rodents analogous to what has been
described for other viruses, including DENV, where the viral
NS2B3 and NS5 proteins promote degradation of human but not
mouse STING and STAT2 (79–82). Alternatively, the attenuated
phenotype inmicewas due to the particularOROV strainwe used.
Future studies usingOROVfield isolates will be needed to address
this issue more definitively.
In summary, our study establishes that the induction of type I
IFN through MAVS, IRF-3, and IRF-7 is essential to control
OROV infection in mice, and this likely occurs dominantly in
nonmyeloid cells. The disease, associated with OROV infection of
immunocompromisedmice, causedmarked hepatic injury.Given
the extent of OROV infection in the liver of Ifnar/mice, hepa-
tocytes may require IFN signaling to avoid targeting by OROV.
The animal models described here may be useful for understand-
ing the basic biology of OROV, an emerging infectious disease
with epidemic potential, as well as testing new candidate thera-
peutics.
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